Last mentioned: Feb 26, 2026
A wave of Q4 2025 earnings reports from mid-cap leaders across healthcare, automotive, and retail sectors highlights a bifurcated recovery. While MedTech and high-end retail show margin expansion, the EV and industrial sectors continue to navigate significant production and scaling headwinds.
NovoCure and Supernus Pharmaceuticals reported Q4 2025 results, highlighting a pivotal year for commercial expansion in oncology and CNS markets. Both companies are navigating the transition from R&D-heavy phases to sustained commercial growth following key regulatory milestones.
Axon Enterprise is set to report Q4 2025 results, with investors focused on the adoption of AI-driven tools like Draft One and the continued rollout of TASER 10. Meanwhile, specialty pharma players Corcept and Supernus prepare to disclose their own year-end performance amid shifting regulatory and competitive landscapes.
Supernus Pharmaceuticals and Corcept Therapeutics are preparing to report Q4 2025 results, with investors focusing on CNS product growth and cortisol-modulating pipeline progress. These reports will provide critical data on market penetration for key therapies like Qelbree and Korlym amidst a shifting regulatory landscape.
Investors are bracing for Q4 2025 results from Axon Enterprise, Supernus Pharmaceuticals, and Corcept Therapeutics, with Axon looking to maintain its perfect revenue beat streak. While Axon dominates the public safety tech space, the pharmaceutical players face varying expectations regarding clinical pipelines and market penetration for core therapies.